ShowcasesPricing
  1. US-listed companies
  2. PTC THERAPEUTICS, INC.

PTC THERAPEUTICS, INC.PTCT

Market cap
$2.5B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net product revenue-------333429535661
Collaboration revenue-------435550-
Collaboration revenue----------100
Royalty revenue-------555114169
Manufacturing revenue----------8
Revenue35253783194265307381539699938
Cost of Goods and Service, Excluding Amortization Of Intangible Assets-------19324565
Amortization of intangible assets----1523283755117223
Research and development5580122118117172257478541651667
Selling, general and administrative-----154203245286326333
Change in the fair value of contingent consideration------19-48-23126128
Intangible asset impairment---------33218
Settlement of deferred and contingent consideration-------11---
Total operating expenses801252042152593805488139131,1461,377
Total operating expenses801252042152593805488139131,1461,377
Loss from operations-45,397,469-99-167-132-64-116-241-432-374-447-440
Interest expense, net-6,083,6551-2-8-12-13-12-56-86-91-129
Other income (expense), net37,512-0-0-1-101485-58-4910
Loss before income tax benefit (expense)-51,573,575-98-170-142-78-128-240-403-518-587-696
Loss on extinguishment of debt-129,963----------138
Income tax benefit (expense)--5011-012356-28-70
Loss before income tax benefit (expense)-51,573,575-98-170-142-78-128-240-403-518-587-696
Net loss attributable to common stockholders-51,573,575-94-170-142-79-128-252-438-524-559-627
Income tax benefit (expense)--5011-012356-28-70
Net loss attributable to common stockholders-51,573,575-94-170-142-79-128-252-438-524-559-627
Basic-5.18-2.97-------7.43-7.79-8.37
Diluted-5.18-2.97-------7.43-7.79-8.37
Basic-5.18-2.97-------7.43-7.79-8.37
Diluted-5.18-2.97-------7.43-7.79-8.37